Nobistar (Nebivolol)

Nebivolol, the active ingredient in Nobistar, is a beta‑blocker presented as a tablet for oral use. It selectively blocks β1‑adrenergic receptors and also promotes nitric‑oxide‑mediated vasodilation, helping to lower blood pressure and improve cardiac function in adult patients with hypertension or heart failure.

GNH USA supplies Nobistar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance across markets.

Nebivolol is used in cardiovascular therapy to control blood pressure and support heart function. - Hypertension: Reduces systolic and diastolic blood pressure, decreasing cardiovascular risk. - Chronic heart failure (NYHA class II‑III): Improves left ventricular ejection fraction and alleviates symptoms. - Left ventricular systolic dysfunction: Enhances cardiac output and may reduce hospitalisation rates.

Nebivolol may cause a range of adverse reactions, which are categorised by frequency and severity.

Common Side Effects: - Fatigue - Headache - Dizziness - Bradycardia - Nausea - Peripheral edema

Serious or Rare Side Effects: - Severe bradycardia or heart block - Worsening heart failure - Bronchospasm in patients with asthma or COPD - Allergic reactions such as rash or angioedema - Hepatic dysfunction - Syncope due to hypotension

When prescribing or dispensing Nobistar, consider the following safety measures. - Dose adjustment: Required in patients with severe renal impairment. - Monitor blood pressure: Check regularly after initiation or dose changes. - Heart‑rate monitoring: Watch for clinically significant bradycardia. - Avoid abrupt discontinuation: May cause rebound hypertension. - Caution in asthma or COPD: β‑blockade can exacerbate bronchospasm. - Store at ambient temperature: Keep in the original container, protect from moisture and light.

Nebistar can interact with several drug classes; awareness helps minimise adverse outcomes.

Major Interactions (Avoid): - Co‑administration with other β‑blockers: Increases risk of excessive bradycardia and hypotension. - Potent CYP2D6 inhibitors (e.g., paroxetine, quinidine): May raise nebivolol plasma concentrations. - Calcium‑channel blockers (verapamil, diltiazem): Can enhance negative chronotropic effects.

Moderate Interactions (Monitor Closely): - Diuretics: May potentiate antihypertensive effect; monitor electrolytes. - Insulin or oral hypoglycemics: May mask hypoglycaemia symptoms. - NSAIDs: Can attenuate antihypertensive efficacy; observe blood pressure response.